NCT04161248 2026-02-02
Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
Canadian Cancer Trials Group
Phase EARLY_PHASE1 Recruiting
Clinical Trials
3 trialsNCT06662227 2026-01-20
Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors
Wondercel Biotech (ShenZhen)
Phase EARLY_PHASE1 Recruiting
NCT07205315 2025-12-26
A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
Grit Biotechnology
Phase EARLY_PHASE1 Recruiting